In NSCLC, 15–30% of adenocarcinoma patients possess a gain of function mutation in the K-Ras gene, meaning that for these patients, their tumors fail to respond to EGFR-TKIs (7,8). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.